Volume | 174,264 |
|
|||||
News | - | ||||||
Day High | 8.62 | Low High |
|||||
Day Low | 7.95 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Solid Biosciences Inc | SLDB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
8.51 | 7.95 | 8.62 | 8.77 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,479 | 174,264 | $ 8.13 | $ 1,416,750 | - | 1.81 - 15.05 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:24:35 | 5 | $ 8.2328 | USD |
Solid Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
312.25M | 37.76M | - | 0 | -96.02M | -2.54 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Solid Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SLDB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.89 | 10.08 | 7.95 | 9.01 | 176,121 | -1.62 | -16.38% |
1 Month | 14.82 | 15.05 | 7.95 | 11.28 | 215,804 | -6.55 | -44.20% |
3 Months | 6.90 | 15.05 | 5.40 | 11.01 | 261,891 | 1.37 | 19.86% |
6 Months | 2.12 | 15.05 | 1.81 | 6.49 | 456,357 | 6.15 | 290.09% |
1 Year | 4.83 | 15.05 | 1.81 | 6.38 | 237,985 | 3.44 | 71.22% |
3 Years | 77.25 | 81.90 | 1.81 | 25.62 | 549,861 | -68.98 | -89.29% |
5 Years | 140.40 | 203.70 | 1.81 | 55.14 | 846,033 | -132.13 | -94.11% |
Solid Biosciences Description
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of speciality and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices. |